Step 1 of 8
Presentation & Red-Flag Triage
Quantitative (anosmia/hyposmia) vs qualitative (parosmia/phantosmia) loss; screen red flags → MRI brain + skull base
Olfactory disorders present as quantitative loss — anosmia (complete), hyposmia (partial), or the rarer hyperosmia — or as qualitative distortion — parosmia (a distorted smell to a real stimulus), phantosmia (smell without a stimulus), and cacosmia (a perceived foul odour). They commonly travel with reduced taste (flavour) perception, dysgeusia, nasal obstruction, rhinorrhoea, facial pressure, headache, or neurological symptoms, and the history begins by naming the disorder precisely, because parosmia and phantosmia carry different implications from flat anosmia.
Before the full work-up, the patient is triaged for red flags that demand urgent imaging. Progressive unilateral anosmia, persistent phantosmia, cranial neuropathies, cognitive decline or personality change, visual disturbance, severe headache, weight loss, new neurological deficits, and any suspicion of a skull-base or intracranial tumour each mandate MRI of the brain and skull base (with contrast where a lesion is suspected) and urgent ENT, neurology or neurosurgery referral — an olfactory-groove meningioma classically presents as a slowly progressive unilateral anosmia. Where no red flag is present, the patient proceeds to the comprehensive evaluation. This triage exists because the great majority of olfactory loss is benign and sinonasal or post-viral, but the rare intracranial cause is missed only by failing to ask the red-flag questions.
- Quantitative — anosmia, hyposmia, hyperosmia; Qualitative — parosmia, phantosmia, cacosmia
- Associated — taste change, nasal obstruction, rhinorrhoea, facial pressure, headache, neurological symptoms
- Red flags — progressive unilateral anosmia, persistent phantosmia, cranial neuropathy, cognitive/visual change, weight loss, neuro deficits
- Any red flag → MRI brain + skull base (± contrast) + urgent ENT/neurology/neurosurgery referral
★ High-yield pearls (chapter-wide)
- Nasal endoscopy is the first essential investigation in every olfactory disorder — it is what separates the treatable conductive obstruction from the sensorineural loss and must not be skipped.
- The pivotal distinction is conductive versus sensorineural versus mixed loss — conductive disease (chronic rhinosinusitis, polyps, obstruction) is mechanically reversible, sensorineural disease (post-viral, traumatic, neurodegenerative) is not, and the two are managed entirely differently.
- Post-viral olfactory dysfunction is the commonest cause of permanent anosmia, and olfactory training is its first-line treatment — started early and continued for months.
- Parosmia, distressing as it is, usually signals olfactory-neuron regeneration and a more favourable prognosis than persistent flat anosmia.
- Progressive unilateral or unexplained anosmia, persistent phantosmia, or any cranial-nerve or cognitive sign mandates MRI of the brain and skull base to exclude an olfactory-groove meningioma or other intracranial lesion.
- Olfactory loss can precede the motor features of Parkinson's disease and the cognitive decline of Alzheimer's disease by several years — new unexplained hyposmia in an older adult is a neurological as well as a nasal sign.
- Anosmia with delayed puberty is Kallmann syndrome until proven otherwise — refer for endocrine evaluation rather than treating the nose alone.
- Olfactory training is the evidence-based first-line therapy for most sensorineural olfactory loss — twice daily exposure to four odours for a minimum of twelve weeks, ideally six to twelve months, rotating the odour sets.
- Every patient with persistent anosmia needs mandatory safety counselling — smoke, natural-gas and carbon-monoxide detectors, and disciplined food-spoilage checks — because the loss is a genuine hazard to life.
- A UPSIT score below chance, or failure to react to ammonia and other trigeminal irritants, points to malingering or functional loss rather than true anosmia, and is worth recognising in the medicolegal setting.
Evidence base
3 sources- HIGH
Hummel T, Whitcroft KL, Andrews P · Rhinology · 2023Consensus position paperPMID 37454287
The 2023 international position paper on olfactory dysfunction — the consensus framework for classification, history, mandatory endoscopy, psychophysical testing, imaging, and the evidence-based management (led by olfactory training) of smell disorders.
- HIGH
Schriever VA & Hummel T · Dtsch Arztebl Int · 2023ReviewPMID 36647581
Contemporary review of olfactory dysfunction — the post-infectious, sinonasal, traumatic, neurodegenerative, drug and toxic aetiologies, the diagnostic work-up, and olfactory-training-led treatment.
- MOD
Tang DM & Lee J · World Neurosurg · 2022Systematic review & meta-analysisPMID 35033688
Systematic review and meta-analysis of olfactory-groove meningioma resection — the intracranial lesion that presents as progressive unilateral anosmia and is the reason red-flag loss is imaged with MRI.
Decision tree
The triage screen is the first gate. Classification routes the stable patient to one of the aetiology-keyed pathways below. Cross-cut cards capture the chapter's must-not-miss rules.